GSK re­ports its long-act­ing HIV PrEP tops Gilead­'s Tru­va­da — again

GSK sub­sidiary Vi­iV Health­care is notch­ing an­oth­er win on its score­card for cabote­gravir, the long-act­ing in­jectable it hopes can sup­plant Gilead’s dai­ly pill for HIV pre­ven­tion.

The com­pa­ny re­port­ed back in Ju­ly that a head-to-head study showed that cabote­gravir is 66% more ef­fec­tive than Gilead’s Tru­va­da among men and trans­gen­der women who have sex with men. Now, a sec­ond tri­al sug­gests that the su­pe­ri­or­i­ty al­so holds true in women.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.